# Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours

> **NCT02992912** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 138 (actual)

## Conditions studied

- Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )

## Interventions

- **DRUG:** Anti-PD-L1 antibody atezolizumab
- **PROCEDURE:** SABR

## Key facts

- **NCT ID:** NCT02992912
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11-15
- **Primary completion:** 2022-05-20
- **Final completion:** 2024-10
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02992912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02992912, "Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02992912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*